MedTrace Logo

Venlafaxine for Hot Flashes After Breast Cancer

NCT00198250 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2008-11-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate Venlafaxine as a treatment option for hot flashes in breast cancer survivors. The goals of this study are to assess the effectiveness and toxicity of venlafaxine hydrochloride and identify the psychological, behavioral, and physical outcomes associated with relief of hot flashes in women following treatment for breast cancer.

Conditions

Interventions

DRUG

venlafaxine

Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks

Sponsors & Collaborators

  • Vanderbilt University

    collaborator OTHER

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Janet S Carpenter, PhD · Indiana University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2005-11-30
Completion
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00198250 on ClinicalTrials.gov